BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 30762947)

  • 1. Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.
    Young A; Vummidi D; Visovatti S; Homer K; Wilhalme H; White ES; Flaherty K; McLaughlin V; Khanna D
    Arthritis Rheumatol; 2019 Aug; 71(8):1339-1349. PubMed ID: 30762947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.
    Volkmann ER; Saggar R; Khanna D; Torres B; Flora A; Yoder L; Clements PJ; Elashoff RM; Ross DJ; Agrawal H; Borazan N; Furst DE; Saggar R
    Arthritis Rheumatol; 2014 Jul; 66(7):1900-8. PubMed ID: 24729406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mortality and hospitalization outcomes of interstitial lung disease and pulmonary hypertension in the Singapore systemic sclerosis cohort.
    Noviani M; Saffari SE; Tan JL; Yip JWL; Teng GG; Law WG; Chan GYL; Santosa A; Lim AYN; Hong C; Ng SA; Tay ELW; Ruan W; Yap J; Low AHL
    Semin Arthritis Rheum; 2020 Jun; 50(3):473-479. PubMed ID: 31810742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
    Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
    Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.
    Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V
    Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.
    Launay D; Humbert M; Berezne A; Cottin V; Allanore Y; Couderc LJ; Bletry O; Yaici A; Hatron PY; Mouthon L; Le Pavec J; Clerson P; Hachulla E
    Chest; 2011 Oct; 140(4):1016-1024. PubMed ID: 21474572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary arterial hypertension without affecting hemodynamics and exercise capacity.
    Michelfelder M; Becker M; Riedlinger A; Siegert E; Drömann D; Yu X; Petersen F; Riemekasten G
    Clin Rheumatol; 2017 Feb; 36(2):381-390. PubMed ID: 28028682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotypes, hemodynamic characteristics and prognosis of Chinese patients with systemic sclerosis-associated precapillary pulmonary hypertension: a retrospective study.
    Yuan YP; Yuan P; Su YL; Jiang R; Zhang R; He J; Qiu HL; Luo CJ; Liu JM; Gong SG; Wang L; Zhao QH
    Clin Rheumatol; 2022 Jun; 41(6):1675-1686. PubMed ID: 35099674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies.
    Le Pavec J; Girgis RE; Lechtzin N; Mathai SC; Launay D; Hummers LK; Zaiman A; Sitbon O; Simonneau G; Humbert M; Hassoun PM
    Arthritis Rheum; 2011 Aug; 63(8):2456-64. PubMed ID: 21538327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.
    Gleason JB; Patel KB; Hernandez F; Hadeh A; Highland KB; Rahaghi F; Mehta JP
    Lung; 2017 Aug; 195(4):403-409. PubMed ID: 28456874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All-cause Healthcare Costs and Mortality in Patients with Systemic Sclerosis with Lung Involvement.
    Fischer A; Kong AM; Swigris JJ; Cole AL; Raimundo K
    J Rheumatol; 2018 Feb; 45(2):235-241. PubMed ID: 29142033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary survival study in 91 patients with systemic sclerosis.
    Poormoghim H; Lakeh MM; Mohammadipour M; Talehy-Moineddin S; Sodagari F
    Rheumatol Int; 2011 Dec; 31(12):1577-82. PubMed ID: 20496069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival after lung transplantation in systemic sclerosis. A systematic review.
    Khan IY; Singer LG; de Perrot M; Granton JT; Keshavjee S; Chau C; Kron A; Johnson SR
    Respir Med; 2013 Dec; 107(12):2081-7. PubMed ID: 24113572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.
    Fischer A; Swigris JJ; Bolster MB; Chung L; Csuka ME; Domsic R; Frech T; Hinchcliff M; Hsu V; Hummers LK; Gomberg-Maitland M; Mathai SC; Simms R; Steen VD
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-109-14. PubMed ID: 25372796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
    Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
    Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relevance of high-resolution computed tomographic findings and pulmonary arterial hypertension in systemic sclerosis-associated interstitial lung disease.
    Wangkaew S; Euathrongchit J; Patiwetwitoon S; Prasertwitayakij N; Kasitanon N; Louthrenoo W
    J Med Assoc Thai; 2014 Aug; 97(8):878-85. PubMed ID: 25345265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis.
    Hax V; Bredemeier M; Didonet Moro AL; Pavan TR; Vieira MV; Pitrez EH; da Silva Chakr RM; Xavier RM
    Semin Arthritis Rheum; 2017 Oct; 47(2):228-234. PubMed ID: 28454677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
    Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
    Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.